What Has Been the Progress and Growth of the Diagnostic Biomarkers Market in Recent Years?
The diagnostic biomarkers market has seen considerable growth due to a variety of factors.
• The expansion of the diagnostic biomarkers industry has been swift and considerable in the past few years. The market size is projected to escalate from $65.25 billion in 2024 to $75.67 billion in 2025, representing a compound annual growth rate (CAGR) of 16.0%.
Factors contributing to the previous period growth include the increasing incidence of chronic ailments, advancements in omics technologies, a growing demand for personalized medicine, heightened awareness of early disease screening, and a boom in non-invasive diagnostic practices.
What Can Be Expected from the Diagnostic Biomarkers Market Size?
The diagnostic biomarkers market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for diagnostic biomarkers is anticipated to experience a swift expansion in the forthcoming years. The market predictions place its value at $136.57 billion in 2029, with a compound annual growth rate (CAGR) of 15.9%.
This projected growth is largely due to the rising use of liquid biopsy technology, escalating funding in biomarker studies, a growing emphasis on precision medicine and increasing applications in neurodegenerative disorders. Key trends for the predicted period encompass advancements in the field of artificial intelligence and machine learning, the assimilation of multi-omics approaches, the emergence of point-of-care diagnostic instruments, a shift towards digital biomarkers, an increased reliance on wearable health monitoring devices, and a heightened focus on the validation and standardization of biomarkers.
What Are the Critical Driver Fuelling The Diagnostic Biomarkers Market's Growth?
The diagnostic biomarkers market's expansion is propelled by the increasing incidence of cancer. This rise in cancer prevalence can be attributed to factors such as an aging demographic, shifts in lifestyle, environmental exposures, and enhanced diagnostic abilities. Diagnostic biomarkers are essential in cancer management for they facilitate early detection, accurate diagnosis, and individualized treatment approaches, thus improving patient prognosis. For example, the American Cancer Society, a nonprofit cancer advocacy organization based in the US, reported in January 2024 that there was an increase in cancer cases to 2,001,140 from 1,958,310 in 2023, indicating a growth of 2.19%. This surge in cancer prevalence is supporting the expansion of the diagnostic biomarkers market.
How Is The Diagnostic Biomarkers Market segmented?
The diagnostic biomarkers market covered in this report is segmented –
1) By Product: Safety Biomarkers, Efficacy Biomarkers, Validation Biomarkers
2) By Application: Oncology, Metabolic Disease, Neurological Disease
3) By End User: Hospitals, Cancer Research Institutes, Diagnostic Labs
Subsegments:
1) By Safety Biomarkers: Toxicity Biomarkers, Organ-Specific Safety Biomarkers, Drug-Induced Injury Biomarkers
2) By Efficacy Biomarkers: Predictive Biomarkers, Prognostic Biomarkers, Pharmacodynamic Biomarkers
3) By Validation Biomarkers: Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers
Pre-Book The Diagnostic Biomarkers Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What New Trends Are Influencing The Diagnostic Biomarkers Market?
Leading enterprises in the diagnostic biomarkers sector are channeling their efforts into innovating non-invasive testing approaches such as blood-based biomarker tests, in an attempt to increase patient comfort and enable personalized treatment plans. Blood-based biomarker tests are diagnostic tools designed to probe specific biological markers in the bloodstream for the purpose of detecting or keeping track of diseases like Alzheimer's with minimal intrusion. Taking the case of Quanterix Corporation, a life sciences firm based in the US, that in July 2023, introduced LucentAD, a blood-based biomarker test purpose-built to aid healthcare professionals in the diagnosis of Alzheimer's disease (AD) in patients who display signs of early cognitive difficulties. This test gauges the plasma levels of a biomarker known as phosphorylated tau protein at the 181 residue (p-Tau 181), which is linked to amyloid pathology in the brain - a major indicator of AD. LucentAD intends to simplify the diagnosis process for potential Alzheimer's patients by offering a diagnostic tool that is both less intrusive and more readily accessible than conventional methods such as cerebrospinal fluid analysis or amyloid positron emission tomography.
Who Are the Key Players In The Diagnostic Biomarkers Market?
Major companies operating in the diagnostic biomarkers market are:
• Johnson & Johnson Services Inc.
• F. Hoffmann-La Roche AG
• Thermo Fisher Scientific Inc.
• Abbott Laboratories
• PerkinElmer Inc.
• Siemens Healthineers AG
• Merck KGaA
• Agilent Technologies Inc.
• Charles River Laboratories International Inc.
• Bio-Rad Laboratories Inc.
• Bruker Corporation
• Qiagen N.V.
• Myriad Genetics Inc.
• Meso Scale Diagnostics LLC
• EKF Diagnostics Holdings Plc
• Sino Biological Inc.
• Enzo Biochem Inc.
• Biomarker Technologies Inc.
• Cisbio Bioassays
• Signosis Inc.
• Epigenomics AG
• LifeSign LLC
• Banyan Biomarkers Inc.
• Biosims Technologies SAS
What Is The Most Dominant Region In The Diagnostic Biomarkers Market?
North America was the largest region in the diagnostic biomarkers market in 2024. The regions covered in the diagnostic biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
